Comprehensive genetic analysis of cytarabine sensitivity in a cell-based model identifies polymorphisms associated with outcome in AML patients

Eric R. Gamazon; Jatinder K. Lamba; Stanley Pounds; Amy L. Stark; Heather E. Wheeler; Xueyuan Cao; Hae K. Im; Amit K. Mitra; Jeffrey E. Rubnitz; Raul C. Ribeiro; Susana Raimondi; Dario Campana; Kristine R. Crews; Shan S. Wong; Marleen Welsh; Imge Hulur; Lidija Gorsic; Christine M. Hartford; Wei Zhang; Nancy J. Cox; M. Eileen Dolan

doi:10.1182/blood-2012-10-464149

Comprehensive genetic analysis of cytarabine sensitivity in a cell-based model identifies polymorphisms associated with outcome in AML patients

Eric R. Gamazon, Jatinder K. Lamba, Stanley Pounds, Amy L. Stark, Heather E. Wheeler, Xueyuan Cao, Hae K. Im, Amit K. Mitra, Jeffrey E. Rubnitz, Raul C. Ribeiro, Susana Raimondi, Dario Campana, Kristine R. Crews, Shan S. Wong, Marleen Welsh, Imge Hulur, Lidija Gorsic, Christine M. Hartford, Wei Zhang, Nancy J. CoxM. Eileen Dolan^*

^*Corresponding author for this work

Preventive Medicine

Research output: Contribution to journal › Article › peer-review

37 Scopus citations

Abstract

Awhole-genome approach was used to investigate the genetic determinants of cytarabineinduced cytotoxicity. We performed a meta-analysis of genome-wide association studies involving 523 lymphoblastoid cell lines (LCLs) from individuals of European, African, Asian, and African American ancestry. Several of the highest-ranked single-nucleotide polymorphisms (SNPs) were within the mutated in colorectal cancers (MCC) gene. MCC expression was induced by cytarabine treatment from1.7- to 26.6-fold in LCLs.A total of 33 SNPs ranked at the top of the meta-analysis (P < 10^-5) were successfully tested in a clinical trial of patients randomized to receive low-dose or high-dose cytarabine plus daunorubicin and etoposide; of these, 18 showed association (P < .05) with either cytarabine 50% inhibitory concentration in leukemia cells or clinical response parameters (minimal residual disease, overall survival (OS), and treatment-relatedmortality). This count (n518) was significantly greater than expected by chance (P5 .016). For rs1203633, LCLs with AA genotype weremore sensitive to cytarabine-induced cytotoxicity (P 5 1.31310⁶) andAA (vs GA or GG) genotype was associated with poorer OS (P 5 .015), likely as a result of greater treatment-related mortality (P 5 .0037) in patients with acute myeloid leukemia (AML). This multicenter AML02 study trial was registered at www.clinicaltrials.gov as #NCT00136084.

Original language	English (US)
Pages (from-to)	4366-4376
Number of pages	11
Journal	Blood
Volume	121
Issue number	21
DOIs	https://doi.org/10.1182/blood-2012-10-464149
State	Published - May 23 2013

ASJC Scopus subject areas

Hematology
Biochemistry
Cell Biology
Immunology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1182/blood-2012-10-464149

Cite this

Gamazon, E. R., Lamba, J. K., Pounds, S., Stark, A. L., Wheeler, H. E., Cao, X., Im, H. K., Mitra, A. K., Rubnitz, J. E., Ribeiro, R. C., Raimondi, S., Campana, D., Crews, K. R., Wong, S. S., Welsh, M., Hulur, I., Gorsic, L., Hartford, C. M., Zhang, W., ... Dolan, M. E. (2013). Comprehensive genetic analysis of cytarabine sensitivity in a cell-based model identifies polymorphisms associated with outcome in AML patients. Blood, 121(21), 4366-4376. https://doi.org/10.1182/blood-2012-10-464149

@article{d9b1fbb495e0493dafad6e5e9667aaac,

title = "Comprehensive genetic analysis of cytarabine sensitivity in a cell-based model identifies polymorphisms associated with outcome in AML patients",

abstract = "Awhole-genome approach was used to investigate the genetic determinants of cytarabineinduced cytotoxicity. We performed a meta-analysis of genome-wide association studies involving 523 lymphoblastoid cell lines (LCLs) from individuals of European, African, Asian, and African American ancestry. Several of the highest-ranked single-nucleotide polymorphisms (SNPs) were within the mutated in colorectal cancers (MCC) gene. MCC expression was induced by cytarabine treatment from1.7- to 26.6-fold in LCLs.A total of 33 SNPs ranked at the top of the meta-analysis (P < 10-5) were successfully tested in a clinical trial of patients randomized to receive low-dose or high-dose cytarabine plus daunorubicin and etoposide; of these, 18 showed association (P < .05) with either cytarabine 50% inhibitory concentration in leukemia cells or clinical response parameters (minimal residual disease, overall survival (OS), and treatment-relatedmortality). This count (n518) was significantly greater than expected by chance (P5 .016). For rs1203633, LCLs with AA genotype weremore sensitive to cytarabine-induced cytotoxicity (P 5 1.313106) andAA (vs GA or GG) genotype was associated with poorer OS (P 5 .015), likely as a result of greater treatment-related mortality (P 5 .0037) in patients with acute myeloid leukemia (AML). This multicenter AML02 study trial was registered at www.clinicaltrials.gov as #NCT00136084.",

author = "Gamazon, {Eric R.} and Lamba, {Jatinder K.} and Stanley Pounds and Stark, {Amy L.} and Wheeler, {Heather E.} and Xueyuan Cao and Im, {Hae K.} and Mitra, {Amit K.} and Rubnitz, {Jeffrey E.} and Ribeiro, {Raul C.} and Susana Raimondi and Dario Campana and Crews, {Kristine R.} and Wong, {Shan S.} and Marleen Welsh and Imge Hulur and Lidija Gorsic and Hartford, {Christine M.} and Wei Zhang and Cox, {Nancy J.} and Dolan, {M. Eileen}",

note = "Funding Information: This work was supported by grants from: the Leukemia and Lymphoma Society, Specialized Center of Research grant (M.E.D.); the National Institutes of Health, National Institute of General Medical Sciences grant U01 GM61393 (M.E.D., N.J.C.); the National Human Genome Research Institute R21HG006367 (W.Z., M.E.D.); Clinical Therapeutics, Training grant 5T32GM007019 (C.M.H.); the Department of Defense, Breast Cancer Research Program grant BC087674 (M.W.); the National Institutes of Health, National Cancer Institute, Cancer Biology Training grants T32CA009594 (H.E.W.) and R01CA132946 (J.K.L.); and the Cancer Research Foundation of the University of Chicago Comprehensive Cancer Center (M.E.D.). Publisher Copyright: {\textcopyright} 2013 by The American Society of Hematology.",

year = "2013",

month = may,

day = "23",

doi = "10.1182/blood-2012-10-464149",

language = "English (US)",

volume = "121",

pages = "4366--4376",

journal = "Blood",

issn = "0006-4971",

publisher = "American Society of Hematology",

number = "21",

}

Gamazon, ER, Lamba, JK, Pounds, S, Stark, AL, Wheeler, HE, Cao, X, Im, HK, Mitra, AK, Rubnitz, JE, Ribeiro, RC, Raimondi, S, Campana, D, Crews, KR, Wong, SS, Welsh, M, Hulur, I, Gorsic, L, Hartford, CM, Zhang, W, Cox, NJ & Dolan, ME 2013, 'Comprehensive genetic analysis of cytarabine sensitivity in a cell-based model identifies polymorphisms associated with outcome in AML patients', Blood, vol. 121, no. 21, pp. 4366-4376. https://doi.org/10.1182/blood-2012-10-464149

TY - JOUR

T1 - Comprehensive genetic analysis of cytarabine sensitivity in a cell-based model identifies polymorphisms associated with outcome in AML patients

AU - Gamazon, Eric R.

AU - Lamba, Jatinder K.

AU - Pounds, Stanley

AU - Stark, Amy L.

AU - Wheeler, Heather E.

AU - Cao, Xueyuan

AU - Im, Hae K.

AU - Mitra, Amit K.

AU - Rubnitz, Jeffrey E.

AU - Ribeiro, Raul C.

AU - Raimondi, Susana

AU - Campana, Dario

AU - Crews, Kristine R.

AU - Wong, Shan S.

AU - Welsh, Marleen

AU - Hulur, Imge

AU - Gorsic, Lidija

AU - Hartford, Christine M.

AU - Zhang, Wei

AU - Cox, Nancy J.

AU - Dolan, M. Eileen

N1 - Funding Information: This work was supported by grants from: the Leukemia and Lymphoma Society, Specialized Center of Research grant (M.E.D.); the National Institutes of Health, National Institute of General Medical Sciences grant U01 GM61393 (M.E.D., N.J.C.); the National Human Genome Research Institute R21HG006367 (W.Z., M.E.D.); Clinical Therapeutics, Training grant 5T32GM007019 (C.M.H.); the Department of Defense, Breast Cancer Research Program grant BC087674 (M.W.); the National Institutes of Health, National Cancer Institute, Cancer Biology Training grants T32CA009594 (H.E.W.) and R01CA132946 (J.K.L.); and the Cancer Research Foundation of the University of Chicago Comprehensive Cancer Center (M.E.D.). Publisher Copyright: © 2013 by The American Society of Hematology.

PY - 2013/5/23

Y1 - 2013/5/23

N2 - Awhole-genome approach was used to investigate the genetic determinants of cytarabineinduced cytotoxicity. We performed a meta-analysis of genome-wide association studies involving 523 lymphoblastoid cell lines (LCLs) from individuals of European, African, Asian, and African American ancestry. Several of the highest-ranked single-nucleotide polymorphisms (SNPs) were within the mutated in colorectal cancers (MCC) gene. MCC expression was induced by cytarabine treatment from1.7- to 26.6-fold in LCLs.A total of 33 SNPs ranked at the top of the meta-analysis (P < 10-5) were successfully tested in a clinical trial of patients randomized to receive low-dose or high-dose cytarabine plus daunorubicin and etoposide; of these, 18 showed association (P < .05) with either cytarabine 50% inhibitory concentration in leukemia cells or clinical response parameters (minimal residual disease, overall survival (OS), and treatment-relatedmortality). This count (n518) was significantly greater than expected by chance (P5 .016). For rs1203633, LCLs with AA genotype weremore sensitive to cytarabine-induced cytotoxicity (P 5 1.313106) andAA (vs GA or GG) genotype was associated with poorer OS (P 5 .015), likely as a result of greater treatment-related mortality (P 5 .0037) in patients with acute myeloid leukemia (AML). This multicenter AML02 study trial was registered at www.clinicaltrials.gov as #NCT00136084.

AB - Awhole-genome approach was used to investigate the genetic determinants of cytarabineinduced cytotoxicity. We performed a meta-analysis of genome-wide association studies involving 523 lymphoblastoid cell lines (LCLs) from individuals of European, African, Asian, and African American ancestry. Several of the highest-ranked single-nucleotide polymorphisms (SNPs) were within the mutated in colorectal cancers (MCC) gene. MCC expression was induced by cytarabine treatment from1.7- to 26.6-fold in LCLs.A total of 33 SNPs ranked at the top of the meta-analysis (P < 10-5) were successfully tested in a clinical trial of patients randomized to receive low-dose or high-dose cytarabine plus daunorubicin and etoposide; of these, 18 showed association (P < .05) with either cytarabine 50% inhibitory concentration in leukemia cells or clinical response parameters (minimal residual disease, overall survival (OS), and treatment-relatedmortality). This count (n518) was significantly greater than expected by chance (P5 .016). For rs1203633, LCLs with AA genotype weremore sensitive to cytarabine-induced cytotoxicity (P 5 1.313106) andAA (vs GA or GG) genotype was associated with poorer OS (P 5 .015), likely as a result of greater treatment-related mortality (P 5 .0037) in patients with acute myeloid leukemia (AML). This multicenter AML02 study trial was registered at www.clinicaltrials.gov as #NCT00136084.

UR - http://www.scopus.com/inward/record.url?scp=84880435476&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84880435476&partnerID=8YFLogxK

U2 - 10.1182/blood-2012-10-464149

DO - 10.1182/blood-2012-10-464149

M3 - Article

C2 - 23538338

AN - SCOPUS:84880435476

SN - 0006-4971

VL - 121

SP - 4366

EP - 4376

JO - Blood

JF - Blood

IS - 21

ER -

Comprehensive genetic analysis of cytarabine sensitivity in a cell-based model identifies polymorphisms associated with outcome in AML patients

Abstract

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this